Citadel Advisors’s Regenxbio RGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $145K | Buy |
17,300
+5,600
| +48% | +$58.8K | ﹤0.01% | 11714 |
|
|
2025
Q4 | $168K | Sell |
11,700
-5,000
| -30% | -$62.3K | ﹤0.01% | 11191 |
|
|
2025
Q3 | $161K | Sell |
16,700
-4,000
| -19% | -$35.4K | ﹤0.01% | 11481 |
|
|
2025
Q2 | $170K | Buy |
20,700
+9,300
| +82% | +$77.8K | ﹤0.01% | 10840 |
|
|
2025
Q1 | $81.5K | Sell |
11,400
-33,700
| -75% | -$251K | ﹤0.01% | 11739 |
|
|
2024
Q4 | $349K | Buy |
45,100
+25,700
| +132% | +$241K | ﹤0.01% | 9346 |
|
|
2024
Q3 | $204K | Buy |
19,400
+1,200
| +7% | +$14.6K | ﹤0.01% | 10118 |
|
|
2024
Q2 | $213K | Sell |
18,200
-4,300
| -19% | -$66.9K | ﹤0.01% | 9792 |
|
|
2024
Q1 | $474K | Buy |
22,500
+6,100
| +37% | +$109K | ﹤0.01% | 8523 |
|
|
2023
Q4 | $294K | Sell |
16,400
-2,000
| -11% | -$35.2K | ﹤0.01% | 9195 |
|
|
2023
Q3 | $303K | Sell |
18,400
-4,700
| -20% | -$85.2K | ﹤0.01% | 9153 |
|
|
2023
Q2 | $462K | Buy |
23,100
+8,700
| +60% | +$168K | ﹤0.01% | 8124 |
|
|
2023
Q1 | $272K | Buy |
14,400
+5,900
| +69% | +$131K | ﹤0.01% | 9569 |
|
|
2022
Q4 | $193K | Sell |
8,500
-5,300
| -38% | -$120K | ﹤0.01% | 10202 |
|
|
2022
Q3 | $365K | Sell |
13,800
-2,100
| -13% | -$62.3K | ﹤0.01% | 9144 |
|
|
2022
Q2 | $393K | Buy |
15,900
+3,400
| +27% | +$84.9K | ﹤0.01% | 9177 |
|
|
2022
Q1 | $415K | Sell |
12,500
-8,700
| -41% | -$242K | ﹤0.01% | 9820 |
|
|
2021
Q4 | $693K | Buy |
21,200
+900
| +4% | +$30.6K | ﹤0.01% | 8869 |
|
|
2021
Q3 | $851K | Buy |
20,300
+6,800
| +50% | +$245K | ﹤0.01% | 8548 |
|
|
2021
Q2 | $524K | Buy |
13,500
+400
| +3% | +$14.3K | ﹤0.01% | 9962 |
|
|
2021
Q1 | $447K | Sell |
13,100
-3,300
| -20% | -$141K | ﹤0.01% | 9925 |
|
|
2020
Q4 | $744K | Sell |
16,400
-13,600
| -45% | -$475K | ﹤0.01% | 7402 |
|
|
2020
Q3 | $826K | Buy |
30,000
+16,100
| +116% | +$525K | ﹤0.01% | 6380 |
|
|
2020
Q2 | $512K | Sell |
13,900
-22,500
| -62% | -$839K | ﹤0.01% | 7028 |
|
|
2020
Q1 | $1.18M | Buy |
36,400
+3,300
| +10% | +$137K | ﹤0.01% | 5040 |
|
|
2019
Q4 | $1.36M | Sell |
33,100
-29,600
| -47% | -$1.17M | ﹤0.01% | 5045 |
|
|
2019
Q3 | $2.23M | Buy |
62,700
+44,100
| +237% | +$1.79M | ﹤0.01% | 4313 |
|
|
2019
Q2 | $955K | Sell |
18,600
-2,500
| -12% | -$125K | ﹤0.01% | 5769 |
|
|
2019
Q1 | $1.21M | Sell |
21,100
-14,200
| -40% | -$703K | ﹤0.01% | 5245 |
|
|
2018
Q4 | $1.48M | Sell |
35,300
-2,000
| -5% | -$117K | ﹤0.01% | 4658 |
|
|
2018
Q3 | $2.82M | Buy |
37,300
+15,400
| +70% | +$1.11M | ﹤0.01% | 3836 |
|
|
2018
Q2 | $1.57M | Buy |
+21,900
| New | +$1.05M | ﹤0.01% | 4464 |
|
Other funds holding RGNX
RG
VCM
IHAM
Citadel Advisors's RGNX Position: Q1 2026 in Review
Citadel Advisors sold out of Regenxbio (RGNX) in Q1 2026, closing a stake of 46,641 shares — an estimated $490K sold.
Citadel Advisors first reported a position in RGNX in Q3 2015 and held it in 38 quarters. The position peaked at $37.1M in Q3 2018. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.
- Citadel Advisors reported no remaining Regenxbio position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 46,641 Regenxbio shares in Q1 2026, an estimated $490K.
- Citadel Advisors first reported a position in Regenxbio in Q3 2015 and held it in 38 quarters.
- Citadel Advisors's Regenxbio position peaked at $37.1M in Q3 2018.
- 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.